Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer
- Substances:InfliximabPembrolizumab+2
Spain- Participants:18–64 years · 65+ years
- Substances:Infliximab
Rare diseases
Investigational molecules
Locations
SpainStudy of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo
SpainStudy to Find Treatments for Chronic Kidney Disease Using Finerenone in Patients with Standard Care
SpainStudy on the Effectiveness and Safety of IMVT-1402 for Adults with Graves' Disease
SpainStudy of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness
SpainStudy comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer
SpainStudy Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
SpainStudy Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer
SpainStudy on ITI-1284 for Treating Agitation in Alzheimer's Patients
SpainStudy Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer
Spain
SpainStudy of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.